Sells SUBLOCADE, a long-acting buprenorphine injection for opioid use disorder, for patients treated by healthcare providers and health systems. Also sells buprenorphine-based sublingual medicines for opioid use disorder.
10-K for FY2025, filed Feb 26, 2026SUBLOCADE (buprenorphine extended-release monthly injection); and SUBOXONE Film (buprenorphine and naloxone sublingual film);View ↗
The FDA approved SUBLOCADE (buprenorphine extended-release injection for subcutaneous use) in November 2017 and we launched sales of this…View ↗
Our sales, marketing, and distribution processes begin with a focus on the patient. Our products are intended for patients who suffer from…View ↗
Wholesalers, specialty pharmacies and specialty distributors buy the medicines; a sale is completed when the customer receives the product. Government programs and commercial insurers have separate pricing arrangements.
10-K for FY2025, filed Feb 26, 2026
$1.2B
10-K for FY2025, filed Feb 26, 2026
$1.2B ↗
Wholesalers, specialty pharmacies and specialty distributors buy directly, then distribute medicines through insurance, government programs and pharmacies. Outside the U.S., products also move through wholesalers, hospitals, pharmacies and individuals.
10-K for FY2025, filed Feb 26, 2026In the U.S., we have distribution agreements with the three largest wholesalers, which accounted for 51% and 55% of our global net revenue…View ↗
Commercial managed care. This category comprises insurance programs intended to reduce the cost of providing health benefits and improve…View ↗
In the Rest of World, distribution channels differ by country and we may engage with different wholesalers, pre-wholesalers, hospitals…View ↗
Net revenue is generated from sales of pharmaceutical products, net of discounts and accruals for returns, incentives and rebates…View ↗
Yes. It kept 17 cents of every revenue dollar as net income in FY2025, but spent more cash than it brought in: free cash flow was −$93M.
8-K, filed Aug 3, 2026
On August 1, 2026, Indivior Pharmaceuticals, Inc., a Delaware corporation (“Indivior”) and Artemis Merger Sub Inc., a Delaware corporation…View ↗
8-K, filed Aug 3, 2026
$1,215 million to $1,285 million $1,295 million to $1,365 millionView ↗
Competes with Camurus
10-K for FY2025, filed Feb 26, 2026For example, SUBLOCADE is patent protected in the U.S., Australia, and Canada. However, Camurus, in partnership with its U.S. marketing…View ↗
Loading...